A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
نویسندگان
چکیده
منابع مشابه
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
INTRODUCTION Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associated with treatment of patients with diffuse cutaneous (dc)SSc with the TKI nilotinib (Tasigna™). ...
متن کاملTreatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
OBJECTIVES The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches. METHODS This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four proto...
متن کاملfrom linguistics to literature: a linguistic approach to the study of linguistic deviations in the turkish divan of shahriar
chapter i provides an overview of structural linguistics and touches upon the saussurean dichotomies with the final goal of exploring their relevance to the stylistic studies of literature. to provide evidence for the singificance of the study, chapter ii deals with the controversial issue of linguistics and literature, and presents opposing views which, at the same time, have been central to t...
15 صفحه اولStabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study.
Volume 43, no. 5 Study Diffuse Skin Involvement following Rituximab Treatment: An Open-label Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with KEYSER and MAURIZIO CUTOLO RUARO, ALBERTO SULLI, ELS VANDECASTEELE, KARIN MELSENS, FILIP DE BRUSSELLE, MICHEL DE PAUW, ELLEN DESCHEPPER, YVES PIETTE, BARBARA VANESSA SMITH, CARMEN PIZZORNI, VALERIA RICCIERI, SASKIA DECUMAN,...
متن کاملImatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
OBJECTIVE To assess the safety and effectiveness of imatinib mesylate in the treatment of diffuse cutaneous systemic sclerosis (dcSSc). METHODS In this phase IIa, open-label, single-arm clinical trial, 30 patients with dcSSc were treated with imatinib 400 mg daily. Patients were monitored monthly for safety assessments. Modified Rodnan skin scores (MRSS) were assessed every 3 months. Pulmonar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ Open
سال: 2021
ISSN: 2044-6055,2044-6055
DOI: 10.1136/bmjopen-2020-044483